Publications by authors named "K Ihrig"
Ramucirumab beyond progression plus TAS-102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab-based therapy.
Int J Cancer
November 2023
Based on results of prior trials (TAGS, REGARD, RAINBOW), the combination of ramucirumab beyond progression with TAS-102 (trifluridine/tipiracil) seems to be promising in advanced esophagogastric adenocarcinoma (EGA). In this multicenter, non-randomized, open-label, investigator-initiated pilot trial, ramucirumab-pretreated patients with metastatic EGA received a maximum of 4 cycles of ramucirumab (8 mg/kg i.v.
View Article and Find Full Text PDFArticle Synopsis
- Glioblastoma (GB) is currently incurable, and this study tested the safety and feasibility of using HER2-targeted chimeric antigen receptor (CAR)-NK cells in patients with recurrent GB, aiming to find a treatment option.
- Nine patients received varying doses of irradiated CAR-NK cells during surgery for their recurrent HER2-positive GB, and a range of follow-up analyses were conducted to assess the immune response and treatment effects.
- The results showed no severe side effects from the treatment, with some patients experiencing stable disease for weeks, and the study determined that the maximum safe dose of CAR-NK cells for further trials is 1 × 108 cells.
Article Synopsis
- Treatment concepts in oncology are becoming personalized and diverse, requiring continuous monitoring of patient care through real-world data, which the DKTK's Clinical Communication Platform (CCP) facilitates.
- The CCP connects 14 cancer centers and analyzes data from over 600,000 patients, focusing on diverse demographic details, diagnoses, treatment responses, and extensive biosample collections.
- Through its sizable and detailed dataset, the cohort aids translational cancer research, enhances understanding of various cancers, and supports clinical trial design and evaluation in real-world settings.
Cure rates in adult acute lymphoblastic leukemia (ALL) improved using pediatric-based chemotherapy and stem cell transplantation (SCT). However, limited data on the health condition of cured adults are available whereas pediatric data cannot be transferred. The GMALL analyzed the health status in survivors of adult ALL retrospectively.
View Article and Find Full Text PDFBackground: The secondary use of deidentified but not anonymized patient data is a promising approach for enabling precision medicine and learning health care systems. In most national jurisdictions (e.g.
View Article and Find Full Text PDF